Osalmid Inhibits the Progression of Lung Adenocarcinoma and Sensitizes It to EGFR-TKIs: A Preclinical and Translational Study

被引：0
|
作者：
Wu, L. -L. [1 ]
Jiang, W. -M. [1 ]
Wang, R. -R. [2 ]
Xie, D. [2 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Shanghai Pulm Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.03I.14
引用
收藏
页码：S315 / S315
页数：1
相关论文
共 50 条
  • [21] Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma.
    Jiang, Kan
    Lin, Gen
    Zheng, Xinlong
    Long, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma harboring EGFR-RAD51 Fusion: A Brief Report
    Wang, H.
    Peng, K.
    Li, A.
    Wang, Z.
    Xie, Z.
    Chen, H.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S624 - S624
  • [23] PMDA issues reminder of lung disease with EGFR-TKIs
    Reactions Weekly, 2016, 1619 (1) : 4 - 4
  • [24] CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma
    Song, Seongeun
    Rhee, Sangmyung
    GENES & GENOMICS, 2025, 47 (03) : 331 - 340
  • [25] Clinical model to predict progression-free survival in EGFR-mutant lung adenocarcinoma patients treated with first-generation EGFR-TKIs
    Cui, Shaohua
    Xiong, Liwen
    Lou, Yuqing
    Shi, Huangping
    Gu, Aiqin
    Zhao, Yizhuo
    Chu, Tianqing
    Wang, Huimin
    Zhang, Wei
    Dong, Lili
    Jiang, Liyan
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (04) : 476 - 485
  • [26] Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
    In Ae Kim
    Jong Sik Lee
    Hee Joung Kim
    Wan Seop Kim
    Kye Young Lee
    BMC Cancer, 18
  • [27] Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
    Wang, H.
    Li, M.
    Xing, R.
    Wei, C.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1110 - S1110
  • [28] Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma
    Yi, Guangming
    Cai, Fanghao
    Liu, Liangzhong
    Liao, Rongxin
    Jiang, Xuan
    Yang, Zhenzhou
    Zhang, Xiaoyue
    FUTURE ONCOLOGY, 2024, 20 (40) : 3477 - 3490
  • [29] Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
    Kim, In Ae
    Lee, Jong Sik
    Kim, Hee Joung
    Kim, Wan Seop
    Lee, Kye Young
    BMC CANCER, 2018, 18
  • [30] Successful Treatment of Switching EGFR-TKIs for Advanced Lung Adenocarcinoma Due to Interstitial Lung Disease: A Case Report
    Zeng, Xianghua
    Wang, Ting
    Tang, Ying
    Liao, Xingyun
    Wang, Jianghong
    Li, Yongsheng
    CURRENT CANCER DRUG TARGETS, 2024,
12345